bioMérieux – First-Quarter 2020 Business Review

16 April, 2020

Marcy l'Étoile (France), April 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, released its business review for the three months ended March 31, 2020.

  • bioMérieux fully mobilized agaist COVID-19 pandemic
  • Organic growth of more than 20% at constant exchange rates and scope of consolidation over the first quarter:
    • €769 million in sales
    • Up 21.5% as reported
  • Sharp sales increase for molecular biology product lines, driven by exceptional demand for respiratory tests
  • Negative impact expected from the slowdown in routine laboratory business, but only minor effects observed so far
  • 2020 objectives withdrawn due to a lack of visibility on all the consequences of the global health crisis

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In this unprecedented health crisis, the in vitro diagnostics industry is playing a crucial role in the fight against the COVID-19 epidemic. Since January, bioMérieux has been working hard to develop SARS-CoV-2 diagnostic solutions for health professionals. Some of the solutions are already available to laboratories, while others will round them out soon. Our teams have shown unwavering commitment to developing, manufacturing and delivering our diagnostic solutions and supporting our customers. Given the unprecedented and rapidly evolving nature of the crisis, we have withdrawn our objectives until we have better visibility".

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 43 countries and serves more than 160 countries with the support of a large network of distributors. In 2018, revenues reached €2.4 billion, with over 90% of international sales.

bioMérieux provides diagnostic solutions (systems, reagents, software, and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP

 

Corporate website: www.biomerieux.com Investor website: www.biomerieux-finance.com

Contacts

Investor Relations

bioMérieux
Sylvain Morgeau
Tel.: +33 (0)4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMérieux
Aurore Sergeant
Tel.: +33 (0)4 78 87 20 53
media@biomerieux.com

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64
lheilbronn@image7.fr

Claire Doligez
Tel.: +33 (0)1 53 70 74 48
cdoligez@image7.fr

Download the Full Press Release:

Download
Pioneering Diagnostics